Transasia Bio-Medicals eyes Rs. 300 crore revenue for 2019-20 from Indian Hematology markets
Hyderabad April 13, 2019: Transasia Bio-Medicals is planning to get Rs. 300 crorers from Indian Hematalogy markets for the financial year 2019-20 and accordingly the company is planing its expansion and spread its markets in the state of Telangana.
Regarded as one among the leading global players in-vitro Diagnostics (IVD) Transiasia Bio-Tech has announced that the company is focusing on the healthcare markets of Telangana on the occasion of its 40th anniversary celebrations.
Backed by European R&D, the company has unveiled 3-Part Differential (3PD) to 5-Part Differential (5PD) fully automated haematology analyzers, reagents and controls. with an aim to provide best technology, the comapny offers a number of features in its diagnostic equipments that help institutions, clinicians and lab technologists for getting accurate diagnosis.
Manufactured by Erba Lachema (100% owned subsidiary of Transasia) in Europe, the H 360, H 560 and ELite 580 hematology analyzers are widely used in the European market. Hematology analyzers are extensively used in patient and research settings to count and characterize blood cells for disease detection and monitoring. Basic analyzers return a complete blood count (CBC) with a three-part differential white blood cell (WBC) count.
Sophisticated analyzers measure cell morphology and can detect small cell populations to diagnose rare blood conditions. The new hematology range are relevant for Telangana, where recent studies have shown growing number of children born have unique and high incidence of hemoglobinopathies like thalassemia and sickle cell anemia. Especially Nizamabad, Adilabad and Warangal, where the custom of consanguineous marriages has caused a rise in the number of thalassemic babies. Screening of all pregnant women helps in early detection and that’s where Transasia’s hematology range comes in.
Addressing the media, Suresh Vazirani, Chairman & Managing Director, Transasia Bio-Medicals Ltd., said, “Telangana is very close to our heart as Hyderabad is where we established our first zonal office in India and also sold our first cell counter in 1983. 3-4 years ago, the Telangana State Medical Services Infrastructure Development Corporation (TSMSIDC), which was established for equitable access to drugs and diagnostic services, especially in the interiors of the state, trusted Transasia by purchasing 5 part differential haematology analyzers for 13-15 medical college hospitals in remote areas. Today every district hospital in Telangana has a Transasia equipment. That is how closely we have been associated with serving the people of the state and we hope with the new range that this close association only grows further. We are encouraged by the initial response to the new range and will be targeting Rs. 300 crores in revenues from Indian market this fiscal.”